Blood-based biomarkers (BMs) in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI + bevacizumab (Bev), cetuximab (Cetux) or Bev + Cetux: Results from CALGB 80405


- Citation:
- J Clin Oncol vol 34 (suppl) abstr 3597
- Meeting Instance:
- ASCO 2016
- Year:
- 2016
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Parents:
- None
- Children:
- 3616